Literature DB >> 4120372

Reaction mechanism of the alternative pathway of complement fixation.

P J Lachmann, P Nicol.   

Abstract

Mesh:

Substances:

Year:  1973        PMID: 4120372     DOI: 10.1016/s0140-6736(73)91886-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  33 in total

1.  Purification of cobra venom factor from phospholipase A contaminant.

Authors:  P J Lachmann; L Halbwachs; A Gewurz; H Gewurz
Journal:  Immunology       Date:  1976-12       Impact factor: 7.397

2.  Complement activation in patients with Gambian sleeping sickness.

Authors:  B M Greenwood; H C Whittle
Journal:  Clin Exp Immunol       Date:  1976-04       Impact factor: 4.330

3.  Glomerular deposition of properdin in Henoch-Schönlein syndrome and idiopathic focal nephritis.

Authors:  D J Evans; D G Williams; D K Peters; J G Sissons; J M Boulton-Jones; C S Ogg; J S Cameron; B I Hoffbrand
Journal:  Br Med J       Date:  1973-08-11

4.  Complement activation in children with acute malaria.

Authors:  B M Greenwood; M J Brueton
Journal:  Clin Exp Immunol       Date:  1974-10       Impact factor: 4.330

Review 5.  The properdin pathway: an "alternative activation pathway" or a "critical amplification loop" for C3 and C5 activation?

Authors:  Richard A Harrison
Journal:  Semin Immunopathol       Date:  2017-11-22       Impact factor: 9.623

6.  Role of caseinase from Aeromonas salmonicida in activation of hemolysin.

Authors:  R W Titball; A Bell; C B Munn
Journal:  Infect Immun       Date:  1985-09       Impact factor: 3.441

7.  Effects of suramin on complement, blood clotting, fibrinolysis and kinin formation.

Authors:  V Eisen; C Loveday
Journal:  Br J Pharmacol       Date:  1973-12       Impact factor: 8.739

8.  Complement studies in children with treated coeliac disease after gluten challenge.

Authors:  C Bosch; M Becker; H W Rotthauwe; W Opferkuch
Journal:  Eur J Pediatr       Date:  1980-08       Impact factor: 3.183

9.  The influence of C3b inactivator (KAF) concentration on the ability of serum to support complement activation.

Authors:  P J Lachmann; L Halbwachs
Journal:  Clin Exp Immunol       Date:  1975-07       Impact factor: 4.330

10.  A general method for affinity purification of complement component C3b using factor H-sepharose.

Authors:  J D Scott; J E Fothergill
Journal:  Biochem J       Date:  1982-09-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.